Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | AGXT | P21549 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL223449 | 0.98 | KIF11 (0.47) | KIF11KCNN4TAAR1IDO1AGXT | |
| SCHEMBL8233131 | 0.81 | TAAR1 (0.55) | KIF11TAAR1IDO1TSHRMAPK1 | |
| SCHEMBL7903555 | 0.79 | KCNN4 (0.44) | KIF11KCNN4TAAR1PTPN1ACHE | |
| SCHEMBL3038006 | 0.79 | KCNN4 (0.44) | KIF11KCNN4TAAR1IDO1AGXT | |
| Hydrochloric Acid SCHEMBL3917461 | 0.79 | TAAR1 (0.53) | KIF11TAAR1IDO1TSHRMAPK1 | |
| SCHEMBL3886392 | 0.78 | KIF11 (0.49) | KIF11TAAR1IDO1AGXTPNMT | |
| SCHEMBL29112294 | 0.78 | KIF11 (0.49) | KIF11TAAR1IDO1ACHE | |
| Ethylamine SCHEMBL27485678 | 0.78 | TAAR1 (0.52) | KIF11KCNN4TAAR1IDO1TSHR | |
| SCHEMBL2260664 | 0.78 | TAAR1 (0.57) | KIF11KCNN4TAAR1IDO1AGXT | |
| Hydrochloric Acid SCHEMBL3886496 | 0.76 | KIF11 (0.47) | KIF11TAAR1IDO1AGXTPNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126848-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021202781-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-07 | — | — | WO | disclosed |
| US-8299100-B2 | Potent and selective neuronal nitric oxide synthase inhibitors with improved membrane permeability | NORTHWESTERN UNIVERSITY (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299100-B2 | Potent and selective neuronal nitric oxide synthase inhibitors with improved membrane permeability | NORTHWESTERN UNIVERSITY (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299100-B2 | Potent and selective neuronal nitric oxide synthase inhibitors with improved membrane permeability | NORTHWESTERN UNIVERSITY (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100190230-A1 | Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors with Improved Membrane Permeability | NORTHWESTERN UNIVERSITY | 2010-07-29 | — | — | US | disclosed |
| US-20100190230-A1 | Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors with Improved Membrane Permeability | NORTHWESTERN UNIVERSITY | 2010-07-29 | — | — | US | disclosed |
| US-20100190230-A1 | Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors with Improved Membrane Permeability | NORTHWESTERN UNIVERSITY | 2010-07-29 | — | — | US | disclosed |
| WO-2010085749-A2 | POTENT AND SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS WITH IMPROVED MEMBRANE PERMEABILITY | NORTHWESTERN UNIVERSITY (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010085749-A2 | POTENT AND SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS WITH IMPROVED MEMBRANE PERMEABILITY | NORTHWESTERN UNIVERSITY (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190230-A1 | Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors with Improved Membrane Permeability | NOS1, NOS2, NOS3 | KIF11 4170/4885KCNN4 704/4885TAAR1 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.